INS and type 1 diabetes mellitus: In light of the current literature, it can be postulated that the second-generation incretin analogs semaglutide and tirzepatide may be valid allies of the advanced technologies employed for the management of T1D, particularly by preventing or treating excess body weight, reducing insulin resistance and insulin requirements, and enhancing the glycemic and metabolic benefits of AID systems.